ReviewFrontiers in public health2026
Epidemiology of invasive meningococcal disease in the United States: review of recent data and identified risk factors.
Review in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Invasive Meningococcal Disease-Changes in Epidemiologic Trends and Outcome over 24 Years in a Tertiary Care Hospital from Romania.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tracking the spread of invasive meningococcal disease (IMD) in the United States is important for identifying risk factors and devising public health strategies to prevent infection. Methods: The epidemiology of IMD in the United States before, during, and after the COVID-19 pandemic (2016-2024) was assessed using surveillance data from the National Notifiable Diseases Surveillance System (NNDSS) and the Enhanced Meningococcal Disease Surveillance program (EMDS). Results: IMD case numbers declined during the pandemic (2020-2021) to 208 in 2021 but rebounded to 312 in 2022 and have continued to increase through 2024 (provisionally 477 cases). In 2022, serogroup C was the predominant serogroup (107 cases), followed by serogroup B (61 cases). Except during the pandemic, IMD cases were higher among those attending versus not attending college. During and after the pandemic, groups with the highest IMD incidence were those <1 year of age (range, 0.38-0.56 cases per 100,000 persons) and within the Black population (range, 0.09-0.19 cases per 100,000 persons). The percentage of IMD cases occurring after the pandemic in men who have sex with men and those with HIV increased substantially from during the pandemic. The percentage of IMD cases that occurred among people experiencing homelessness (PEH) was relatively high, ranging from 2.4-6.3%. Conclusion: The data indicate a rebound in IMD after the COVID-19 pandemic, highlighting the importance of strengthening surveillance and vaccination among high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.